Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?
Gafni
Amiram
A
Department of Clinical Epidemiology and Biostatistics and the Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, ON. gafni@fhs.mcmaster.ca
Birch
Stephen
S
D003362:Cost-Benefit Analysis; D003657:Decision Making; D005569:Formularies as Topic; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D009864:Ontario; D004364:Pharmaceutical Preparations / Q000191:economics*; D010606:Pharmacy and Therapeutics Committee
D004364:Pharmaceutical Preparations